• FK866 (APO866): Precision NAMPT Inhibition in AML Research

  2026-06-08

  FK866 (APO866) delivers unparalleled specificity as a NAMPT inhibitor for dissecting NAD metabolism in hematologic malignancies. This article reveals optimized workflows, troubleshooting guidance, and cross-study insights for translational researchers pursuing innovative acute myeloid leukemia (AML) models.

• Sodium Salicylate: Deep Dive into NF-κB Inhibition and Strom

  2026-06-07

  Explore how sodium salicylate acts as an NF-κB inhibitor and its advanced applications for oxidative stress reduction in tumor stroma research. This article uniquely bridges molecular mechanism with translational assay decision-making.

• Optimizing Immunoassays with HyperFluor™ 488 Rabbit Anti-Goa

  2026-06-06

  HyperFluor™ 488 Rabbit Anti-Goat IgG (H+L) Antibody offers researchers robust, low-background signal amplification across Western blotting, immunofluorescence, IHC, and flow cytometry. Its Alexa Fluor 488 conjugation and high specificity streamline workflows and enhance the detection of goat primary antibodies in even the most challenging biological samples.

• Nadolol (SQ-11725) in Research: Transporter Interplay and PK

  2026-06-05

  Explore how Nadolol (SQ-11725) enables precise dissection of beta-adrenergic signaling and transporter-mediated pharmacokinetics in hypertension and vascular headache research. This article uniquely bridges OATP1A2 transport, disease modeling, and practical protocol design.

• Docetaxel in Cancer Chemotherapy Research: Advanced Workflow

  2026-06-05

  Docetaxel is a cornerstone for modeling apoptosis and chemoresistance in cutting-edge cancer research. This article delivers actionable workflows, protocol optimizations, and troubleshooting insights for maximizing experimental reproducibility with APExBIO’s Docetaxel across tumor models.

• Anlotinib Hydrochloride: Optimizing Angiogenesis & Cell Assa

  2026-06-04

  This article provides scenario-driven, evidence-based guidance for researchers using Anlotinib hydrochloride (SKU C8688) in angiogenesis and cell viability workflows. Drawing from peer-reviewed data and practical lab experience, the piece details how this multi-target tyrosine kinase inhibitor ensures reproducibility and sensitivity for migration and tube formation assays. Researchers are equipped to make informed choices grounded in validated protocols and direct performance comparisons.

• BRCA2 Modulates PARP1 Retention and RAD51 Filament Stability

  2026-06-04

  This study uncovers how BRCA2 prevents PARP inhibitor-induced PARP1 retention at DNA damage sites, thereby safeguarding RAD51 filament stability during homologous recombination. These findings clarify a key mechanism underlying the sensitivity of BRCA2-deficient tumors to PARP inhibitors and have direct implications for targeted cancer research and therapy.

• Aclacinomycin A (SKU A2601): Reliable DNA Damage & Apoptosis

  2026-06-03

  This article addresses common laboratory challenges in cytotoxicity and apoptosis assays, demonstrating how Aclacinomycin A (SKU A2601) provides reproducible, well-characterized solutions for DNA damage induction and cell death pathway analysis. Leveraging recent literature and validated performance data, it guides researchers in optimizing workflows for sensitive, high-fidelity results.

• SAR405: Precision Vps34 Inhibitor for Autophagy Research

  2026-06-03

  SAR405 enables researchers to specifically dissect autophagy and vesicle trafficking pathways with unmatched selectivity. Its robust inhibitory profile and compatibility with advanced cell models make it indispensable for investigating lysosomal function and cancer signaling.

• Alosetron (SKU A3157): Optimizing 5-HT3 Antagonist Use in GI

  2026-06-02

  This article navigates key lab scenarios where Alosetron (SKU A3157) streamlines gastrointestinal cell viability and stem cell fate assays. By grounding recommendations in reproducibility and reference data, it empowers scientists to make informed, evidence-driven choices for 5-HT3 receptor signaling studies.

• CCR7–Notch1 Crosstalk Maintains Stemness in Mammary Cancer C

  2026-06-02

  Boyle et al. (2017) reveal a mechanistic intersection between CCR7 and Notch1 signaling in MMTV-PyMT mammary tumor cells, showing that their crosstalk sustains cancer stem-like properties. This finding points to the therapeutic potential of dual targeting these axes to disrupt breast cancer stemness and recurrence.

• Protease Inhibitor Cocktail: Broad-Spectrum Protein Protecti

  2026-06-01

  The Protease Inhibitor Cocktail (100X in DMSO, EDTA plus) provides robust, broad-spectrum inhibition of serine, cysteine, aspartic, and metalloproteases. This solution, formulated by APExBIO, ensures effective protein degradation prevention and reliable results in workflows such as Western blotting, immunoprecipitation, and kinase assays.

• SAR405: Precision Vps34 Inhibitor for Autophagy Inhibition

  2026-06-01

  SAR405 empowers researchers with nanomolar precision to dissect autophagy and vesicle trafficking pathways, offering exceptional selectivity for Vps34. Its unique profile, verified in recent signaling studies, positions SAR405 as an indispensable tool for advanced disease modeling and functional autophagy assays.

• CIP2A Modulates PKM2 Tetramerization and OXPHOS in NSCLC Met

  2026-05-31

  The reference study reveals that the oncoprotein CIP2A promotes oxidative phosphorylation in non-small cell lung cancer (NSCLC) by inducing PKM2 tetramerization and mitochondrial localization. These findings challenge conventional views of tumor metabolism and highlight new intervention points for cancer research.

• Unlocking mRNA Delivery Precision: ARCA Cy5 EGFP mRNA (5-moU

  2026-05-30

  Explore how ARCA Cy5 EGFP mRNA (5-moUTP) and 5-methoxyuridine modified mRNA enable advanced, immune-silent assays for mRNA localization and translation. This article uniquely dissects practical workflow advances and translational insights beyond current literature.

444 records 15/30 page Previous Next First page 上5页 1112131415 下5页 Last page